BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15778081)

  • 1. FLT-3: a new focus in the understanding of acute leukemia.
    Markovic A; MacKenzie KL; Lock RB
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
    Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
    Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 Inhibitors in the Treatment of AML.
    Gilliland DG
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
    Spiekermann K; Hiddemann W; Schnittger S
    Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
    [No Abstract]   [Full Text] [Related]  

  • 5. FLT3: ITDoes matter in leukemia.
    Levis M; Small D
    Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.
    Schmidt-Arras DE; Böhmer A; Markova B; Choudhary C; Serve H; Böhmer FD
    Mol Cell Biol; 2005 May; 25(9):3690-703. PubMed ID: 15831474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplified capillary electrophoresis detection of the Flt-3 internal tandem duplications and D835 point mutations in acute myeloid leukemia.
    Chang TL; Salto-Tellez M; Kueh YK; Koay ES
    Haematologica; 2003 Feb; 88(2):ELT04. PubMed ID: 12604435
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of FLT3 in haematopoietic malignancies.
    Stirewalt DL; Radich JP
    Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
    Martinelli G; Piccaluga PP; Lo Coco F
    Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathophysiology and treatment of acute myeloid leukemia].
    Naoe J
    Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
    [No Abstract]   [Full Text] [Related]  

  • 12. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
    Reilly JT
    Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
    Doepfner KT; Boller D; Arcaro A
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
    Sternberg DW; Licht JD
    Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic receptor tyrosine kinase in leukemia.
    Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
    Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.
    Torrent M; Rickert K; Pan BS; Sepp-Lorenzino L
    J Mol Graph Model; 2004 Oct; 23(2):153-65. PubMed ID: 15363457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 inhibition in acute myeloid leukaemia.
    Knapper S
    Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
    Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
    Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.